Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-31, Stock:ABBV, The news for the past five days is as follows:
2018-07-24: NEWS1: Citron's Left reiterates belief AbbVie shares will fall sharply.NEWS2: AbbVie prices new endometriosis drug at $10,000 a year.NEWS3: Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?.NEWS4: Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?.NEWS5: Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?.NEWS6: Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?.NEWS7: Merck (MRK) Q2 Earnings Coming Up: What&apos;s in the Cards?.NEWS8: AbbVie Wins U.S. Approval for Endometriosis Pain Treatment.NEWS9: AbbVie Gets Approval for Endometriosis Pain Treatment.NEWS10: AbbVie Gets OK for Potential Blockbuster Endometriosis Treatment.NEWS11: Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?.NEWS12: What's in Store for Cardinal Health (CAH) in Q4 Earnings?.NEWS13: What's in Store for Cardinal Health (CAH) in Q4 Earnings?.NEWS14: AbbVie wins FDA approval for oral treatment for endometriosis pain.NEWS15: Eli Lilly Surpasses Estimates, Reports Growth in Q2 2018.NEWS16: AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis.NEWS17: What to Expect When AbbVie Reports Q2 Earnings.NEWS18: What to Expect When AbbVie Reports Q2 Earnings.NEWS19: What&apos;s in Store for Cardinal Health (CAH) in Q4 Earnings?.NEWS20: J&J’s Oncology Franchise Saw 42.2% Growth in Q2 2018.NEWS21: What to Expect When AbbVie Reports Q2 Earnings.NEWS22: Validea John Neff Strategy Daily Upgrade Report - 7/24/2018.NEWS23: Validea John Neff Strategy Daily Upgrade Report - 7/24/2018.NEWS24: AbbVie Reports FDA Approval Of ORILISSA - Quick Facts.NEWS25: AbbVie Reports FDA Approval Of ORILISSA - Quick Facts.NEWS26: What’s Next for Pfizer Stock After Being Called Out by President Trump.NEWS27: What’s Next for Pfizer Stock After Being Called Out by President Trump.NEWS28: Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?.NEWS29: Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?.
2018-07-25: NEWS1: AbbVie Secures FDA Approval for Endometriosis Drug Elagolix.NEWS2: AbbVie Secures FDA Approval for Endometriosis Drug Elagolix.NEWS3: 3 'Strong Buy' Healthcare Stocks Poised to Surge.NEWS4: AbbVie Secures FDA Approval for Endometriosis Drug Elagolix.NEWS5: In pursuit of Alzheimer&apos;s, cancer, growing Alector lands $133 million.
2018-07-26: NEWS1: 5 Must-See Earnings Charts to End the Week.NEWS2: 5 Must-See Earnings Charts to End the Week.NEWS3: Keller Lenkner LLC Files Class Action Suit Against AbbVie Inc..NEWS4: Pre-Market Earnings Report for July 27, 2018 :  XOM, CVX, MRK, ABBV, CL, PSX, AON, MCO, TWTR, IMO, WY, SYF.NEWS5: Pre-Market Earnings Report for July 27, 2018 :  XOM, CVX, MRK, ABBV, CL, PSX, AON, MCO, TWTR, IMO, WY, SYF.NEWS6: A guide to biotech’s building boom in South City.NEWS7: Notable ETF Inflow Detected - IUSG, ABBV, CRM, PYPL.NEWS8: Notable ETF Inflow Detected - IUSG, ABBV, CRM, PYPL.NEWS9: AbbVie Q2 Earnings Preview.NEWS10: How The Pieces Add Up: RNDV Headed For $24.NEWS11: How The Pieces Add Up: RNDV Headed For $24.NEWS12: How Gilead Sciences Fared in the Second Quarter.NEWS13: Stryker Reports Revenue Growth of 10.3% in Second Quarter.NEWS14: ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions.
2018-07-27: NEWS1: 2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited.NEWS2: 2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited.NEWS3: Health Care Sector Update for 07/27/2018: SGEN,NBRV,ABBV,TNXP.NEWS4: Health Care Sector Update for 07/27/2018: SGEN,NBRV,ABBV,TNXP.NEWS5: Noteworthy Friday Option Activity: SBUX, ABBV, ZBH.NEWS6: Noteworthy Friday Option Activity: SBUX, ABBV, ZBH.NEWS7: 2 Reasons the Market Frowned After AbbVie&apos;s Blowout Q2 -- and 1 Reason It Should Be Excited.NEWS8: Health Care Sector Update for 07/27/2018: NBRV,ABBV,TNXP.NEWS9: Health Care Sector Update for 07/27/2018: NBRV,ABBV,TNXP.NEWS10: AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up.NEWS11: AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up.NEWS12: US STOCKS-Tech, healthcare stocks weigh on Wall Street.NEWS13: AbbVie cash cow Humira barely beats sales estimates, stock slides.NEWS14: Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV&apos;s Elagolix Gets FDA Nod.NEWS15: Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales.NEWS16: Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales.NEWS17: AbbVie&apos;s (ABBV) Q2 Earnings Beat Estimates, 2018 View Up.NEWS18: How AbbVie Makes its Money.NEWS19: Morning Movers: Amazon Shines Amid GDP Fizzle.NEWS20: Morning Movers: Amazon Shines Amid GDP Fizzle.NEWS21: AbbVie (ABBV) Tops Q2 Earnings and Revenues, View Up.NEWS22: AbbVie (ABBV) Tops Q2 Earnings and Revenues, View Up.NEWS23: AbbVie (ABBV) Beats Q2 Earnings and Revenue Estimates.NEWS24: Varian Medical Systems’ Fiscal Q3 2018 Performance.NEWS25: Analyzing AstraZeneca’s Q2 2018 Performance.NEWS26: Vertex Pharmaceuticals Registers Strong Revenue Growth In Q2.NEWS27: How Baxter International Fared in the Second Quarter.NEWS28: Bristol-Myers Squibb Posts Strong Results in Q2 2018.NEWS29: NovoCure’s Revenues Rose 60% in the Second Quarter.NEWS30: Seattle Genetics Posted Strong Q2 2018 Results, Stock Rose.NEWS31: AbbVie (ABBV) Tops Q2 Earnings and Revenues, View Up.NEWS32: AbbVie reports Q2 profit, revenue beats.NEWS33: AbbVie tops second-quarter estimates, sets higher earnings target.NEWS34: AbbVie Reports Second-Quarter 2018 Financial Results.NEWS35: Earnings Reaction History: AbbVie Inc., 63.6% Follow-Through Indicator, 4.7% Sensitive.NEWS36: Earnings Reaction History: AbbVie Inc., 63.6% Follow-Through Indicator, 4.7% Sensitive.NEWS37: Pharma Favorites: 7 Healthy Picks in the Drug Sector.
2018-07-30: NEWS1: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV.NEWS2: CLASS ACTION UPDATE for ABBV, ORA and SBGL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS3: How Celgene’s Otezla and Abraxane Did in Q2 2018.NEWS4: AbbVie's Stock Is Incredibly Cheap.NEWS5: AbbVie's Stock Is Incredibly Cheap.NEWS6: AbbVie&apos;s Stock Is Incredibly Cheap.NEWS7: Worried About AbbVie? 5 Things the Big Pharma's CEO Just Said You'll Want to Know.NEWS8: Worried About AbbVie? 5 Things the Big Pharma's CEO Just Said You'll Want to Know.NEWS9: Worried About AbbVie? 5 Things the Big Pharma&apos;s CEO Just Said You&apos;ll Want to Know.NEWS10: How AbbVie Fared in Q2 2018.NEWS11: Where to Find Bargains in the S&P 500.NEWS12: European Medicines Agency's CHMP Says Yes To 7 Drugs, No To 1.NEWS13: European Medicines Agency's CHMP Says Yes To 7 Drugs, No To 1.

Answer: Rise